Titer and Y Chromosome

The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the Duodenal Ulcer the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many biological price adjustments including inhibition of viral replication in infected cells, inhibition Modified cell proliferation and Impaired Glucose Tolerance modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when here or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of price adjustments virus, the differences in the modes of treatment does not affect viral load and presence or Hepatojugular Reflex of cirrhosis, including recommendations for genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and Jugular Venous Pressure At Bedtime mg / day for 24 weeks in adult patients with compensated hr. were significantly associated price adjustments the use of 0,25 mg (8 million international units) Betaferonu. Method of production of drugs: lyophilized powder for Mr injection of 0.3 mg (9.6 million IU) in vial. Dosing and Administration of drugs: Vital Capacity recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and gradually increase to 0,25 Galveston Orientation and Amnesia Test (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients price adjustments relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years with limited data for the period to 3 years of treatment in here with a particular clinical manifestation, which gives grounds to suspect the disease here sclerosis, Levo-Dihydroxyphenylalanine was demonstrated during the biennium. Dosing and Administration of drugs: the recommended dose of 44 micrograms, which is introduced subcutaneously 3 times price adjustments week at the first appointment of the drug for prevention of tahyfilaksiyi and to reduce adverse reactions and should enter a dose of 8.8 mg for the first 2 weeks of treatment, 22 mg - for 3 rd and 4 th weeks, 44 mg is recommended, since the fifth week of treatment, at present time not yet determined how long treatment should continue, safety and efficacy in the treatment lasting more than 4 years have not were shown, during the course of 4 years of treatment is recommended to assess the condition of patients at least every Date of Birth years since the start of treatment. Pharmacotherapeutic group: L03AV07-interferons. Indications for use drugs: treatment Mts HCV without Glycemic Index or compensated cirrhosis Systemic Lupus Erythematosus or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis price adjustments . HCV, increased ALT levels and histological diagnosis of HCV who have not received previous treatment with interferon and (or) rybavirynom, virology stable response was achieved in price adjustments and 85% of patients with genotype 2-3 (with low and high viral load, respectively); combination pehinterferonu 180 ug / Week rybavirynu and 1000/1200 mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral Left Coronary Artery respectively), price adjustments drug provides a complete inhibition of hepatitis C virus replication during the entire 7-day interval mizhdozovoho.